focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 101.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 4.00 (4.04%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 101.00
CNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Post-Close Trading Update

4 Jan 2023 07:00

RNS Number : 5749L
Concurrent Technologies PLC
04 January 2023
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain.

 

4 January 2023

Concurrent Technologies Plc

(the 'Company')

 

Post-Close Trading Update

 

Concurrent Technologies Plc (AIM: CNC), a world-leading specialist in the design and manufacture of high-end embedded computer systems and boards for critical applications, is pleased to announce an update on trading for the year ending 31 December 2022 ("FY22").

 

Based on its unaudited management accounts for FY22, the Company expects to report revenues circa 10% ahead of market expectations* and profit before tax at least in line with market expectations**.

 

This was achieved despite the global supply chain shortages which extended lead times throughout the year, delaying manufacture, shipping and revenues. The Company invested significant cash into holding increased inventory to react quickly once parts became available, as happened at the end of FY22. To best manage this recent surge in activity the Company implemented a double shift throughout Q4, resulting in record revenues in November and December 2022. 

 

Cash was depleted throughout the year as a result of the Company's declared strategy of investing in R&D, systems, and growth of its home markets in the US and UK. The additional investment in components holdings to mitigate supply shortages, resulted in a cash low point at the end of FY22, at a value of circa £4M.

 

With the increased shipping of product in November and December 2022, the Company anticipates strong cash generation at the start of FY23, with further episodes of cash generation as components become more available. Whilst overall supply chains are seeing a degree of recovery, the Company is in many cases dependent on some very specific components, and hence FY23 forecasts remain prudently cautious.

 

The Company intends to continue its strategy to invest in growth during FY23, and this includes efforts to make acquisitions that align with a strategy of owning more of the technology building blocks in embedded systems, in addition to single board computers. 

 

FY22 has seen excellent strategic progress. The Company now sells systems products and has received its first purchase orders accordingly. It has also qualified a manufacturing partner in the USA and is therefore capable of selling domestic product in America. In addition, the Company's accelerated R&D efforts are resulting in increased demand for evaluation boards which is the route to being designed into latter production phases that typically last several years.

 

Following a record order intake in FY21 of £25M, the Company is proud to announce order intake for FY22 in excess of £31M, an increase of over 25%. The FY22 closing backlog was also very strong, in excess of £26M. These figures indicate that, as supply chains ease, the Company has potential for significant revenue growth. A further cause for optimism is that the Company expects to run double shifts throughout Q1 FY23, maintaining its increased capacity.

 

The Board previously confirmed a policy of paying dividends from profit generated during the year. Accordingly, the Board does not currently propose to pay a dividend in respect of FY22, with cash instead being used to fund further investment across the business, including in component holdings to mitigate the impact of any potential further restrictions. However, the Board is still committed to the capital discipline of paying a dividend when future profits allow.

 

Chief Executive Officer Miles Adcock said "Whilst the prolonged components shortages have frustratingly slowed down revenue generation, it is clear that our strategy is yielding growth potential. The fact that we have our highest ever backlog, following a record order intake, gives us real optimism for short to mid-term performance growth as supply chains improve. In addition, our longer-term strategies are exciting our customers and colleagues, so it is all to play for."

*Consensus revenue expectations for 2022 are £16m

**Consensus profit before tax expectations for 2022 are £0.1m

 

Enquiries:

Concurrent Technologies Plc

Miles Adcock, CEO +44 (0)1206 752626

Kim Garrod, CFO

 

SEC Newgate (Financial PR)

Bob Huxford +44 (0)20 3757 6880

Isabelle Smurfit +44 (0)20 3757 6880

Harry Handyside concurrent@secnewgate.co.uk

 

Cenkos Securities Plc (NOMAD)

Neil McDonald +44 (0)131 220 9771

Peter Lynch +44 (0)131 220 9772

 

About Concurrent Technologies Plc

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom™ processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded Operating Systems. The products are sold world-wide.

For more information on Concurrent Technologies Plc and its products please visit www.gocct.com.

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOAWROWUARAR
Date   Source Headline
23rd Apr 20207:00 amRNSResults for the year ended 31 December 2019
17th Apr 20207:00 amRNSNotice of Results
26th Mar 20207:00 amRNSDirector Appointment and Results Timing Update
10th Mar 20207:00 amRNSSecond Interim Dividend
14th Feb 20206:06 pmRNSDirector/PDMR Shareholding
12th Feb 202012:18 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSProduct Announcement
24th Jan 20204:29 pmRNSHolding(s) in Company
21st Jan 20207:00 amRNSPost-Close Trading Update
7th Jan 20202:13 pmRNSHolding(s) in Company
7th Jan 20202:10 pmRNSHolding(s) in Company
6th Jan 202012:29 pmRNSHolding(s) in Company
20th Nov 201910:14 amRNSHolding(s) in Company
11th Oct 20191:45 pmRNSDirector/PDMR Shareholding
10th Sep 20197:00 amRNSInterim Results
9th Aug 20197:00 amRNSNotice of Interim Results
11th Jun 20198:45 amRNSProduct Announcement
22nd May 20194:41 pmRNSResult of AGM
21st May 20192:30 pmRNSAGM Statement
8th May 20197:00 amRNSDeath of Director
24th Apr 20197:00 amRNSDistribution of Annual Report and Accounts
4th Apr 20197:00 amRNSResults for the year ended 31 December 2018
29th Mar 20197:00 amRNSNotice of Results
14th Mar 20197:00 amRNSSecond Interim Dividend
6th Mar 20197:00 amRNSProduct Announcement
17th Jan 20192:50 pmRNSPost-Close Trading Update
14th Jan 20192:00 pmRNSLeave of Absence
8th Oct 20187:00 amRNSProduct Announcement
12th Sep 20187:00 amRNSInterim Results
6th Sep 20187:00 amRNSNotification of Interim Results
8th Jun 20187:00 amRNSProduct Announcement
22nd May 20183:41 pmRNSAGM Statement
21st May 20187:00 amRNSProduct Announcement
30th Apr 20189:30 amRNSDistribution of Annual Report and Accounts
4th Apr 20187:00 amRNSResults for the year ended 31 December 2017
3rd Apr 20189:01 amRNSProduct Announcement
28th Mar 20184:03 pmRNSNotice of Results
27th Mar 20182:14 pmRNSProduct Announcement
8th Mar 20187:00 amRNSSecond Interim Dividend
26th Feb 201810:17 amRNSCorrection - Product Announcement
26th Feb 20187:00 amRNSProduct Announcement
21st Feb 20187:00 amRNSProduct Announcement
23rd Jan 20187:00 amRNSProduct Announcement
21st Dec 20177:00 amRNSPre-Close Trading Update
30th Nov 20171:29 pmRNSProduct Announcement
18th Sep 20177:00 amRNSInterim Results for the six months ended 30 Jun 17
5th Sep 20177:00 amRNSNotice of Results
26th Jun 20177:00 amRNSProduct Announcement
25th May 20172:57 pmRNSResult of AGM
9th May 20177:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.